Pseudohypoparathyroidism (PHP) is a rare endocrine disorder caused by genetic mutations that disrupt the body’s ability to respond to parathyroid hormone, leading to imbalances in calcium and phosphate levels. But with growing awareness and breakthroughs in medical science, the landscape of treatment is evolving rapidly! br br 💡 Key Drivers Behind the Rising PHP Market: br br 🔬 Advances in genetic testing & molecular diagnostics are ensuring earlier and more accurate diagnoses br br 💊 Increasing use of recombinant PTH analogs, calcitriol, and phosphate binders to stabilize calcium-phosphate balance br br 🌐 Emerging therapies like long-acting PTH analogues and pathway-targeting small molecules are showing promise br br 🧠 Supportive treatments like calcium & vitamin D supplements continue to improve quality of life br br 🧬 Cutting-edge research in gene therapy and personalized medicine is paving the way for next-gen treatments br br 🌍 Market growth is further supported by better healthcare infrastructure, reimbursement policies, and access in key regions like the US, Europe, and Japan br br Explore how rare genetic disorders like PHP are now in the spotlight, and how innovation is shaping a better future for patients! br br Report Link: br br Contact us: br br IMARC Group br 134 N 4th St., Brooklyn, br NY 11249, USA br Email: sales@imarcgroup.